Breast cancer is the most common cancer in women and the second leading cause of cancer mortality, with more than 2.2 million annual cases and 685,000 estimated deaths globally.
In the clinical practice, patients are classified according to the expression of estrogen receptor (ER), progesterone receptor (PR(, amplificacion of human epidermal growth factor receptor 2 (HER2), and proliferation rate (Ki67 positivity), and base on that classification there is also a different incidence, prognosis and treatment options.
Triple negative breast cancers are a heterogeneous group of tumors that don’t express any of these receptors and that have an aggressive nature with higher rates of relapse and shorter overall survival in the metastatic setting compared with the other subtypes.
In a recently published study, researchers found that MYC inhibitor Omomyc can stop the spread of triple-negative breast cancer in a mice study. The study appears in the journal Cancer Research Communications.
Research Development and Results
Previous research has demonstrated that the expression of the oncoprotein MYC is altered in the majority of cancers. This protein plays a role in promoting most human forms of cancer.
The researchers found that the inhibition of this oncoprotein by transgenic Omomyc is efficacious against all breast cancer molecular subtypes, including the triple-negative breast cancer, showing potent antimetastatic properties in vitro and in vivo, using a mouse model.
Omomyc is a MYC dominant negative designed by the researchers, and comprises the MYC oncoprotein with changes in 4 amino acids. This compound was named OMO-103, and is already in clinical trials Phase I/IIa, which means that its safety and efficacy are currently being tested for the first time in cancer patients.
Daniel Massó-Vallés, et al. MYC inhibition Halts Metastatic Breast Cancer Progression by Blocking Growth, Invasion, and Seeding. Cancer Research Communications. 2022. 2 (2): 110-130. https://doi.org/10.1158/2767-9764.CRC-21-0103
Timothy Huzar. (2022, Mar 17). New therapy may stop metastasis in triple-negative breast cancer. Medical News Today. Retrieved from: